Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Investor Presentation (August 2022)
18 slides from Moleculin Biotech's investor presentation, Aug 18, 2022
Slide 1: Moleculin
-<S/MOLECULIN We i
Slide 2: Disclaimer
Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words "believe,"
Slide 3: Investment Highlights
Investment Highlights Advancing growing pipeline of clinical programs for the trey it of highly resistant | ni) ind viruses i) Annamycin Next generation non-cardiotoxic anthracycline demonstrating both safety and promising early activity across multiple clinical studies Second Lead Program (Ongoing
Slide 4: Priority Development Pipeline
Priority Development Pipeline PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE 2 UPCOMING MILESTONES _ Phase completedin 2 2022: Phase 2 interim data expected H2 2022 Soft Tissue Sarcoma Lung Mets Phase 1b/2 study in Poland expected to ‘commence H2 2022 Annamycin ~ Announced reaching RP2D and preliminar
Slide 5: Management Team with Proven Executional Expertise
Management Team with Proven Executional Expertise zeno BG Sag im Novartis Growaxinn
Slide 6: Leveraging the Brightest Scientific Minds
Leveraging the Brightest Scientific Minds HEMATOLOGY VIROLOGY Memori: in = YS ©) arber sea ENGLAND UC School of Medicine CANCER CENTER Bmovecuin Fr’
Slide 7: Annamycin: Potential to Be an Effective Treatment Across Multiple Oncology Indications
Annamycin: Potential to Be an Effective Treatment Across Multiple Oncology Indications Clinical Highlights Demonstrated preliminary positive data in STS Announced RP2D and preliminary efficacy of 60% ORR in last cohort of single agent AML trial; Enrollment of Phase 1/2 combo AML trial expected to co
Slide 8: Annamycin: Next Generation Anthracycline
Annamycin Next Generation Anthracycline Demonstrated to Be Non-Cardiotoxic! Ability to overcome multi-drug resistance >30x greater accumulation in lungs than doxorubicin Potent topoisomerase-Il poison with a wider therapeutic window than doxorubicin? <10% incidence of alopecia compared with 65%-92%
Slide 9: Annamycin: Ongoing Phase 1b/2 Study for STS Lung Mets
Annamycin Ongoing Phase 1b/2 Study for Treatment of STS Lung Mets " US Multi-Center, Open-Label, Dose Escalation Study 360 mg/m? RP2D. Phase 1b Concluded Phase 2 Recruitment Open RP2D determined to Expansion at 360 mg with option be 360 mg/m? to decrease to 330 mg Preliminary Phase 1b Data Showed No
Slide 10: Annamycin: Phase 1/2 Study for Relapsed or Refractory AML
Annamycin Phase 1/2 Study for Treatment of Relapsed or ~ Refractory (R/R) AML Poland Multi-Center, Open-Label, Dose Escalation Study 240 mg/m? 1, 2& 3 with 21 days off Preclinical data -agent y RP2D established Infusion days Primary Endpoint Met Pivoting to Phase 1/2 single agent trial established A
Slide 11: Annamycin: AML Clinical Benefit to Date
Annamycin AML Clinical Benefit to Date’ 59 R/R AML patients? treated in both US and EU trials preliminary overall response rate in 60% 240 mg single-agent cohort? (including a CRi that qualified for curative BMT) ‘MOLECULIN nied 100% patients taken above the lifetime maximum anthracycline dose estab
Slide 12: The Full Annamycin Opportunity
The Full Annamycin Opportunity Potential for Significant Upside — 60K Pancreatic Liver — 67K 13,500 RCCLune ‘STS Lung Mets —— 67K Endometrial Lung, Initial Annamycin 20,000 104K Target Indications} Acute Myeloid ome Colorectal Leukerria Liver TOTAL INCIDENCE Expansion Indications 5K TOTAL INCIDENCE
Slide 13: WP1122: Phase 1 Study for COVID-19 Also Accelerates Oncology Program
WP1122: Phase 1 Study for COVID-19 also Accelerates Oncology Program Key Highlights Prodrug of glucose decoy enables drug-like properties Targets glycolysis and glycosylation; limits viral infectivity and replication Clinical Highlights Single ascending dose (SAD) cohorts 1 and 2 completed, dosing d
Slide 14: Additional Development Pipeline
Additional Development Pipeline Additional Follow-on Opportunities Provide Potential for Significant Upside PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE 2 UPCOMING MILESTONES IND/CTA targeted for 20 indications valuating Phase 1 stu jate externally funded cl dy; MTD sic a il be supported by UK Phase
Slide 15: Financial Snapshot
Financial Snapshot Nasdaq: MBRX Strong Cash Position Funds Operations Beyond Mid-2024! ~28.5M ~50K Cash Shares 3 Month Avg. Balance? Outstanding* Volume? movecuuin 15
Slide 16: Targeted Value-Driving Milestones
Targeted Value-Driving Milestones Annamycin WP1122 WP10 INDICATION ‘STS(US) sTs(ev) [AML Single Agent ‘AML Combo with Ara-C ‘OVID-19Phase 1 sets MTD for Cancer and Viral Studies Pediatric Brain Tumor Including DPIG 2021 2022 CORR at RP2D Phase 1a First Cohort Phase? Interim Data initiate Phase 1b/ I
Slide 17: Investment Summary
Investment Summary Lead program, Annamycin demonstrating safety and preliminary activity in multiple clinical studies with zero cardiotoxicity WP1122: ongoing Phase 1a study in COVID-19 targeting viral infectivity and replication & supporting possible future oncology and viral trials Additional pipe
Slide 18: Thank You
NASDAQ: MBRX | moleculin.com Thank You! 0 dt co} MOLECULIN ope
Moleculin Biotech — Investor Presentation (August 2022) on 6ix